FDA Grants Approval to Ivosidenib for Patients With R/R Myelodysplastic Syndromes With IDH1 Mutation

On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase-1, in the treatment of patients with relapsed/refractory myelodysplastic syndromes with IDH1 mutation, as identified through an FDA-approved diagnostic test. 

Access the full article to read more here.